Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Bactiguard Holding AB (publ)
  6. News
  7. Summary
    BACTI B   SE0005878741


SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Bactiguard : and schülke sign agreement for wound care in Germany

06/04/2021 | 02:01am EDT

Bactiguard and German company Schülke & Mayr GmbH (schülke) have signed an exclusive distribution agreement for Bactiguard's range of wound care solutions to German hospitals. schülke is one of the leading global manufacturers and distributors within infection prevention and hygiene solutions.

The collaboration enables schülke to complement its comprehensive product range of antiseptic and wound care products with Bactiguard's hypochlorous acid-based portfolio.

"We are excited about the collaboration with schülke and believe our mutual goal of preventing infections is an excellent foundation for the future. Together with schülke we aim to further develop the market for products based on hypochlorous acid - with the ultimate goal of improving patient safety and well-being", says Peter Rådqvist, Global Head of Sales at Bactiguard.

Hypochlorous acid is an antimicrobial substance that reduces the risk of infection and promotes wound healing. It is present in the human immune system and has a favourable biocompatilibity profile, meaning it is not harming human cells. The German launch is scheduled for Q3 2021.

Headquartered outside Hamburg, Germany, schülke is a pioneer in  infection prevention and hygiene solutions with more than 130 years of experience in providing disinfection and wound care products. The company is represented in more than 100 countries and has more than 1,000 employees globally. The agreement means that schülke will distribute Bactiguard's wound care solutions to German hospitals.

Bactiguard's new wound care range
Bactiguard's wound care range is a non-alcoholic, pH-neutral and water-based product line that can be used by both children and adults. The products are biocompatible, which means that they are not irritating to the skin or other tissue. They contain hypochlorous acid, the same substance as the body's immune cells use in their defence against infectious organisms. The products neither smell strongly or sting, but effectively kill most virus, bacteria and fungi that cause infections, including the new coronavirus SARS-CoV-2.1

Read more about Bactiguard's wound care range >>>

For further information, please contact:
Petra Kaur, Chief Marketing and Communication Officer, mobile +46 79 304 96 36

1. In collaboration with the Swedish Veterinary Institute (SVA), tests have been carried out with Hydrocyn aqua on a virus culture of the new Coronavirus (SARS-CoV-2) that causes covid-19. The results showed that 99.98% of the virus particles were inactivated - and thus not contagious.

About Bactiguard

Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission, we develop and supply infection prevention solutions which reduce the risk of infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large.

The Bactiguard technology is based on a thin noble metal alloy coating that prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through licence agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Urinary catheters with Bactiguard's coating are market leaders in the USA and Japan through our licensing partner BD.

Bactiguard's product portfolio also includes a non-alcoholic product line for wound care and disinfection. It effectively kills viruses, bacteria and fungi while being biocompatible, pH neutral and tissue friendly. The active ingredient hypochlorous acid is the same substance as the body's immune cells use in their defence against infectious organisms.

Bactiguard is in a strong expansion phase in the markets in Europe, China, India and the Middle East through our own product portfolio and by establishing licensing deals in new therapy areas. 

Bactiguard has about 180 employees around the world. Its headquarters and one of three production facilities are located in Stockholm, the other two in Malaysia. Bactiguard is listed on Nasdaq Stockholm.
Read more about Bactiguard www.bactiguard.com

About schülke
The company is a leader in the field of infection prevention and hygiene solutions for more than 130 years. Schülke & Mayr GmbH develops, produces and distributes antiseptics for wound care, disinfectants and medical and cosmetic skin care products. The company offers its customers innovative products, solutions and services in the professional healthcare business, over the counter (OTC) and hygiene solutions for the pharma sector. schülkes mission is to protect lives worldwide and thereby actively contributes to patient safety. The company is headquartered in Germany, employs more than 1,000 people worldwide and sells its products in more than 100 countries. schülke is represented by 15 subsidiaries and operates production sites in Germany (schülke), France (Bioxal) and Brazil (Vic Pharma). www.schuelke.com



(c) 2021 Cision. All rights reserved., source Press Releases - English

09/21BACTIGUARD : completes a directed new share issue to AMF, raising approximately SEK 228 mi..
09/14BACTIGUARD : Aniocyn, now available in stores in the Nordic region
09/11BACTIGUARD : Sepsis always starts with an infection – causes at least 11 M deaths gl..
09/07Bactiguard Holding AB Appoints Anders Göransson as CEO
09/07BACTIGUARD : appoints new CEO
08/31BACTIGUARD : recruits Chief Licensing Officer to accelerate growth
08/31Bactiguard Appoints Carl Johan Fredin as Chief Licensing Officer
08/25Bactiguard Announces Extension of Tender Award for Wound Care Products for the Public S..
08/25BACTIGUARD : Extended Malaysian wound care tender
07/15BACTIGUARD : Interim report for Q2 2021
More news
Sales 2020 177 M 20,3 M 20,3 M
Net income 2020 -38,4 M -4,42 M -4,42 M
Net Debt 2020 254 M 29,3 M 29,3 M
P/E ratio 2020 -125x
Yield 2020 -
Capitalization 5 085 M 586 M 586 M
EV / Sales 2019 15,5x
EV / Sales 2020 28,6x
Nbr of Employees -
Free-Float 34,3%
Duration : Period :
Bactiguard Holding AB (publ) Technical Analysis Chart | BACTI B | SE0005878741 | MarketScreener
Technical analysis trends BACTIGUARD HOLDING AB (PUBL)
Short TermMid-TermLong Term
Income Statement Evolution
Managers and Directors
Cecilia Marie Edström Chief Executive Officer & Director
Gabriella Björknert Caracciolo Chief Financial Officer & Deputy CEO
Nils Thomas von Koch Chairman
Stefan Grass Chief Medical Officer & Deputy CEO
Sathish Subramaniam Chief Operations Officer